Project Grant R01HL180402
Award Date 8/22/25
Completion Date 5/31/30
Dollars Obligated $722K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award of $756,228.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support a research project to develop an AI-enabled model for predicting outcomes in patients with chronic limb-threatening ischemia (CLTI) who undergo revascularization. The project aims to supplement electronic health record (EHR) and clinical note data with additional patient and caregiver-reported data collected through mobile health apps...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $147,486 to Baylor College of Medicine to study the genetics of cardiovascular disease (CVD) across diverse and mixed-ancestry populations. The key objectives are to improve genetic testing for CVD and lipoprotein A, a lipoprotein that increases CVD risk, by evaluating the role of ancestry-related genetic factors. The research will include genome-wide...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $738,472 to The Trustees of the University of Pennsylvania to develop accurate cardiovascular disease (CVD) risk prediction models for men with prostate cancer. The project aims to improve overall health outcomes in this population by tailoring CVD prevention and management to individual patient risk. Key products will include new risk prediction models...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....
- This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
- The federal Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) seeks to validate and extend a platform technology for the delivery of protein-based thrombolytic drugs. The bioengineering strategy employs the designed assembly of endogenous biomolecules, including thrombolytic enzymes and vitamin B12, to create a biocompatible drug delivery platform that leverages the circulatory system as a natural drug depot and...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $392,037 Project Grant to New York University (NYU) to support research on post-operative biomarker-guided precision medicine for cardiovascular risk reduction. The goal is to carry out an international multi-site randomized clinical trial to evaluate perioperative biomarker-based precision care, using targeted long-term use of low-dose direct oral anticoagulants and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on advancing scientific understanding of the connections between cancer and cardiovascular disease. The $1,102,957 grant awarded to The Leland Stanford Junior University will fund a multidisciplinary research program spanning population genetics, cardio-oncology, and translational medicine. The key objectives are to precisely...
- This federal Project Grant award, titled "VENOUS THROMBOEMBOLISM: ENHANCING REPRESENTATION IN CLINICAL TRIALS AND INVESTIGATION OF SOCIODEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH SECONDARY ANTICOAGULATION USE AND OUTCOMES IN CHILDREN", is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) for $186,153. The award aims to systematically analyze venous thromboembolism (VTE) data from a multicenter prospective cohort study of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $642,454 to The Ohio State University to develop a multimodal AI-based system to predict the risk of treatment-related cardiotoxicity in breast cancer patients. The goal is to enable clinicians to make early decisions about anti-tumor therapies and interventions that can reduce the risk of serious cardiovascular complications, which have become a leading non-malignant cause of death...